Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Veure altres versions (1)

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Descripció completa

Dades bibliogràfiques
Autors principals:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Format:	Journal article
Idioma:	English
Publicat:	2008

Ítems similars

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
per: Clerico, M, et al.
Publicat: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
per: Clerico, M, et al.
Publicat: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
per: Clerico, M, et al.
Publicat: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
per: Clerico, M, et al.
Publicat: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
per: Clerico, M, et al.
Publicat: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
per: Valéria Coelho Santa Rita Pereira, et al.
Publicat: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
per: Clerico, M, et al.
Publicat: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
per: Clerico, M, et al.
Publicat: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
per: GJ Melendez-Torres, et al.
Publicat: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
per: E.J. Ramos González, et al.
Publicat: (2021-05-01)

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
per: Andrew F Tyler, et al.
Publicat: (2013-01-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
per: Clerico, M, et al.
Publicat: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
per: Clerico, M, et al.
Publicat: (2006)

Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report
per: Joanna Roskal-Wałek, et al.
Publicat: (2021-09-01)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
per: N. Y. Lasch
Publicat: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
per: Katarzyna Kapica-Topczewska, et al.
Publicat: (2019-01-01)

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
per: G. J. Melendez-Torres, et al.
Publicat: (2018-10-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
per: G. Ya. Shvarts
Publicat: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
per: Özlem Taşkapılıoğlu, et al.
Publicat: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
per: Özlem Taşkapılıoğlu, et al.
Publicat: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
per: Oscar Fernández
Publicat: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
per: Massimiliano Mirabella, et al.
Publicat: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
per: Mikhail Melnikov, et al.
Publicat: (2020-01-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
per: Oscar Fernández
Publicat: (2012-04-01)

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
per: Niklas Bergvall, et al.
Publicat: (2014-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
per: Methma Udawatta, et al.
Publicat: (2024-04-01)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis
per: Attila Onmez, et al.
Publicat: (2013-12-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
per: Aaron Boster, et al.
Publicat: (2011-09-01)

A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate
per: C. Halasan, et al.
Publicat: (2020-01-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
per: P Tappenden, et al.
Publicat: (2004-06-01)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
per: Caporro M, et al.
Publicat: (2014-08-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
per: Anna Gil-Sánchez, et al.
Publicat: (2024-04-01)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
per: Anne Waschbisch, et al.
Publicat: (2011-01-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
per: Genaro Gabriel Ortíz, et al.
Publicat: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
per: Arielle Kasindi, et al.
Publicat: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
per: Arthur Komlosh, et al.
Publicat: (2019-07-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
per: Ioana S. Barac, et al.
Publicat: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
per: T. E. Shmidt
Publicat: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
per: Ignacio Casanova, et al.
Publicat: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
per: Justin M. Honce, et al.
Publicat: (2020-09-01)